In short
Tegafur is an oral chemotherapy drug being investigated in various clinical trials for treating different types of cancer. As a prodrug of 5-fluorouracil (5-FU), tegafur is often combined with other medications to enhance its effectiveness and reduce side effects. This article summarizes key findings from recent clinical trials exploring tegafur's potential in cancer treatment.
What is Tegafur?
Tegafur is an anticancer drug that belongs to a class of medications called fluoropyrimidines. It is often referred to by its brand names, which include UFT and S-1. Tegafur is a prodrug, which means it is converted into an active form of the medication called 5-fluorouracil (5-FU) in the body.
Conditions Treated with Tegafur
Tegafur is used to treat various types of cancer, including:
- Colorectal cancer: Cancer that starts in the colon or rectum
- Esophageal squamous cell carcinoma: A type of cancer that affects the esophagus (the tube that connects the throat to the stomach)
- Head and neck cancer: Cancers that start in the mouth, nose, throat, or nearby areas
- Hepatocellular carcinoma: The most common type of liver cancer
- Gallbladder carcinoma: Cancer that begins in the gallbladder
- Extrapancreatic neuroendocrine tumors: Rare tumors that develop in hormone-producing cells outside the pancreas
How Tegafur Works
Tegafur works by interfering with the growth of cancer cells. Once it's converted to 5-FU in the body, it inhibits an enzyme called thymidylate synthase (TS). This enzyme is crucial for DNA synthesis, which cancer cells need to grow and divide. By blocking TS, Tegafur helps to slow down or stop the growth of cancer cells.
How Tegafur is Administered
Tegafur is typically given orally (by mouth) in the form of capsules or tablets. The dosage and schedule can vary depending on the specific condition being treated and other factors. Some common administration methods include:
- Daily dosing: For example, 300 mg/m² three times a day
- Twice daily dosing: Such as 40-60 mg twice a day for 14 days in a 21-day cycle
- Dosing based on body surface area: For instance, 40 mg for body surface area <1.25m², 50 mg for 1.25-1.5m², and 60 mg for >1.5m²
Tegafur in Combination Therapies
Tegafur is often used in combination with other medications to enhance its effectiveness. Some common combinations include:
- Tegafur + Uracil (UFT): This combination helps to maintain higher levels of the active drug in the body
- Tegafur + Folinic acid: Folinic acid can enhance the effects of Tegafur
- Tegafur + Oxaliplatin (SOX regimen): Used in treating various gastrointestinal cancers
- Tegafur + Temozolomide: Used in treating neuroendocrine tumors
- Tegafur + Immunotherapy drugs: Such as Adebrelimab and Apatinib, used in advanced esophageal cancer
Ongoing Clinical Trials
Several clinical trials are currently exploring new ways to use Tegafur, including:
- As maintenance therapy after surgery for stage III colon cancer
- In combination with immunotherapy for advanced esophageal cancer
- As part of a metronomic chemotherapy regimen for head and neck cancer
Potential Side Effects
Like all medications, Tegafur can cause side effects. Some potential side effects include:
- Diarrhea
- Nausea and vomiting
- Decreased appetite
- Fatigue
- Bone marrow suppression (which can lead to increased risk of infections, anemia, or bleeding)
- Liver function abnormalities
It's important to note that not everyone experiences these side effects, and your healthcare provider will monitor you closely during treatment.